2357 related articles for article (PubMed ID: 16674999)
1. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
Kamphuisen PW; Agnelli G
Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials.
Wein L; Wein S; Haas SJ; Shaw J; Krum H
Arch Intern Med; 2007 Jul; 167(14):1476-86. PubMed ID: 17646601
[TBL] [Abstract][Full Text] [Related]
4. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
5. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta-analysis.
Själander A; Jansson JH; Bergqvist D; Eriksson H; Carlberg B; Svensson P
J Intern Med; 2008 Jan; 263(1):52-60. PubMed ID: 18088252
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery.
Mismetti P; Laporte S; Darmon JY; Buchmüller A; Decousus H
Br J Surg; 2001 Jul; 88(7):913-30. PubMed ID: 11442521
[TBL] [Abstract][Full Text] [Related]
8. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
[TBL] [Abstract][Full Text] [Related]
9. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
Huo MH; Muntz J
Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
[TBL] [Abstract][Full Text] [Related]
10. Thromboprophylaxis and early antithrombotic therapy in patients with acute ischemic stroke and cerebral venous and sinus thrombosis.
Busch M; Masuhr F
Eur J Med Res; 2004 Apr; 9(4):199-206. PubMed ID: 15210400
[TBL] [Abstract][Full Text] [Related]
11. Reduction in thrombus extension and clinical end points in patients after initial treatment for deep vein thrombosis with the fixed-dose body weight-independent low molecular weight heparin certoparin.
Harenberg J; Huisman MV; Tolle AR; Breddin HK; Kirchmaier CM
Semin Thromb Hemost; 2001 Oct; 27(5):513-8. PubMed ID: 11668421
[TBL] [Abstract][Full Text] [Related]
12. Venous thromboembolism prophylaxis and treatment in patients with acute stroke and traumatic brain injury.
Vergouwen MD; Roos YB; Kamphuisen PW
Curr Opin Crit Care; 2008 Apr; 14(2):149-55. PubMed ID: 18388676
[TBL] [Abstract][Full Text] [Related]
13. Low molecular weight heparin for deep vein thrombosis in glioma patients.
Schmidt F; Faul C; Dichgans J; Weller M
J Neurol; 2002 Oct; 249(10):1409-12. PubMed ID: 12382158
[TBL] [Abstract][Full Text] [Related]
14. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials.
Mismetti P; Laporte-Simitsidis S; Tardy B; Cucherat M; Buchmüller A; Juillard-Delsart D; Decousus H
Thromb Haemost; 2000 Jan; 83(1):14-9. PubMed ID: 10669147
[TBL] [Abstract][Full Text] [Related]
15. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
Colwell C; Mouret P
Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of unfractionated heparin and low molecular weight heparin in pulmonary thromboembolism: meta-analysis].
Zhai ZG; Wang C; Liu YM; Qin ZQ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Jun; 26(3):221-6. PubMed ID: 15266820
[TBL] [Abstract][Full Text] [Related]
17. Low molecular weight heparins in the prevention of venous thromboembolism in nonsurgical patients.
Haas S
Semin Thromb Hemost; 1999; 25 Suppl 3():101-5. PubMed ID: 10549724
[TBL] [Abstract][Full Text] [Related]
18. Preventing venous thromboembolism in medical patients.
Leizorovicz A; Mismetti P
Circulation; 2004 Dec; 110(24 Suppl 1):IV13-9. PubMed ID: 15598642
[TBL] [Abstract][Full Text] [Related]
19. Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy.
DeBernardo RL; Perkins RB; Littell RD; Krasner CN; Duska LR
Obstet Gynecol; 2005 May; 105(5 Pt 1):1006-11. PubMed ID: 15863537
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis of thrombosis with low-molecular-weight heparin (LMWH).
Holzheimer RG
Eur J Med Res; 2004 Mar; 9(3):150-70. PubMed ID: 15096326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
